These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. Levodopa-induced dyskinesia in Parkinson's disease: still no proof? A meta-analysis. Giannakis A; Chondrogiorgi M; Tsironis C; Tatsioni A; Konitsiotis S J Neural Transm (Vienna); 2018 Sep; 125(9):1341-1349. PubMed ID: 29352351 [TBL] [Abstract][Full Text] [Related]
25. Efficacy and safety of entacapone in levodopa/carbidopa versus levodopa/benserazide treated Parkinson's disease patients with wearing-off. Kuoppamäki M; Leinonen M; Poewe W J Neural Transm (Vienna); 2015 Dec; 122(12):1709-14. PubMed ID: 26347184 [TBL] [Abstract][Full Text] [Related]
26. Bromocriptine versus levodopa in early Parkinson's disease. Ramaker C; van Hilten JJ Cochrane Database Syst Rev; 2000; (3):CD002258. PubMed ID: 10908538 [TBL] [Abstract][Full Text] [Related]
27. Blood levodopa levels and unified Parkinson's disease rating scale function: with and without exercise. Goetz CG; Thelen JA; MacLeod CM; Carvey PM; Bartley EA; Stebbins GT Neurology; 1993 May; 43(5):1040-2. PubMed ID: 8492923 [TBL] [Abstract][Full Text] [Related]
32. Receptor Ligands as Helping Hands to L-DOPA in the Treatment of Parkinson's Disease. Del Bello F; Giannella M; Giorgioni G; Piergentili A; Quaglia W Biomolecules; 2019 Apr; 9(4):. PubMed ID: 30970612 [TBL] [Abstract][Full Text] [Related]
33. Pharmacokinetics and efficacy of a novel formulation of carbidopa-levodopa (Accordion Pill LeWitt PA; Giladi N; Navon N Parkinsonism Relat Disord; 2019 Aug; 65():131-138. PubMed ID: 31176632 [TBL] [Abstract][Full Text] [Related]
35. Madopar HBS (hydrodynamically balanced system) in the treatment of Parkinson's disease. Lees AJ Adv Neurol; 1990; 53():475-82. PubMed ID: 2239487 [No Abstract] [Full Text] [Related]
36. Concurrent administration of donepezil HCl and levodopa/carbidopa in patients with Parkinson's disease: assessment of pharmacokinetic changes and safety following multiple oral doses. Okereke CS; Kirby L; Kumar D; Cullen EI; Pratt RD; Hahne WA Br J Clin Pharmacol; 2004 Nov; 58 Suppl 1(Suppl 1):41-9. PubMed ID: 15496222 [TBL] [Abstract][Full Text] [Related]
37. [Benefit of L-DOPA-without-DCI (decarboxylase inhibitor) therapy on wearing-off phenomenon in advanced stages of Parkinson's disease patients]. Hironishi M; Miwa H; Kondo T No To Shinkei; 2002 Feb; 54(2):127-32. PubMed ID: 11889758 [TBL] [Abstract][Full Text] [Related]
38. Corticotroph axis sensitivity after exercise in endurance-trained athletes. Duclos M; Corcuff JB; Arsac L; Moreau-Gaudry F; Rashedi M; Roger P; Tabarin A; Manier G Clin Endocrinol (Oxf); 1998 Apr; 48(4):493-501. PubMed ID: 9640417 [TBL] [Abstract][Full Text] [Related]
39. Mucuna pruriens in Parkinson Disease: A Kinetic-Dynamic Comparison With Levodopa Standard Formulations. Contin M; Lopane G; Passini A; Poli F; Iannello C; Guarino M Clin Neuropharmacol; 2015; 38(5):201-3. PubMed ID: 26366963 [TBL] [Abstract][Full Text] [Related]
40. Revisiting the Medical Management of Parkinson's Disease: Levodopa versus Dopamine Agonist. Zhang J; Tan LC Curr Neuropharmacol; 2016; 14(4):356-63. PubMed ID: 26644151 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]